Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 20, 2009

DiscoveRx Technologies to Support Evotec’s HTS Services

  • Evotec and DiscoveRx inked a co-marketing deal for the screening of GPCR’s and other targets. Evotec will have access to DiscoveRx’ PathHunter™ and cAMPHunter™ cell lines as well as EFC chemiluminescent detection technology for use during hit identification and optimization projects performed for Evotec customers.
     
    DiscoveRx’ EFC-related technologies offer assay solutions for every major class of drug target including GPCRs, kinases, proteases, nuclear hormone receptors, and secreted proteins, the company points out. “For our customers this agreement means that DiscoveRx’ innovative assay portfolio of more than 300 cell-based GPCR assays can be accessed in conjunction with the first-class high-throughput screening set-up at Evotec,” notes Evotec’s evp, business development, Mark Ashton
     


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »